A phase I trial of a new recombinant human β-interferon (BG9015) for the treatment of patients with recurrent gliomas

Howard A. Fine, Patrick Y. Wen, Michael Robertson, Anne O'Neill, Janis Kowal, Jay S. Loeffler, Peter M L Black

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Primary brain tumors represent an important cause of cancer-related morbidity and mortality in the United States. Despite advances in neurosurgery and radiotherapy, the median survival of patients with malignant gliomas remains less than 1 year. A contributing factor to the poor prognoses of these patients is the diffuse, infiltrative nature of these tumors, which limits the effectiveness of focal therapies (i.e. surgery and radiation). Unfortunately, standard chemotherapy has been of limited benefit in the treatment of malignant gliomas, underlying the necessity for new drugs with novel mechanisms of action. On the basis of promising in vitro and clinical data demonstrating significant antiglioma activity of purified IFN-β and a synthetic IFN-β (Betaseron), we conducted a Phase I trial of a new, nonmutated, glycosylated recombinant human IFN-β (BG9015) in patients with recurrent, high-grade astrocytomas. In this trial, we demonstrate that the maximally tolerated dose of BG9015 is 6 million units/m2 delivered by intramuscular injection three times per week. Dose-limiting neurotoxicity was seen in both patients treated at 8 million units/m2. Additionally, we demonstrate that high BG9015 serum levels are associated with a fall in natural killer cell number, radiographic response, and prolonged survival. We conclude that BG9015 has activity in patients with malignant gliomas, although the therapeutic index may be narrow. Future studies will be needed to confirm the observation that natural killer cell number and activity as well as BG9015 serum levels are important markers of antitumor activity.

Original languageEnglish (US)
Pages (from-to)381-387
Number of pages7
JournalClinical Cancer Research
Volume3
Issue number3
StatePublished - 1997
Externally publishedYes

Fingerprint

Glioma
Interferons
Natural Killer Cells
Cell Count
Therapeutics
Survival
Maximum Tolerated Dose
Intramuscular Injections
Astrocytoma
Neurosurgery
Serum
Brain Neoplasms
Neoplasms
Radiotherapy
glycosylated recombinant human INF-beta
Radiation
Morbidity
Drug Therapy
Mortality
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Fine, H. A., Wen, P. Y., Robertson, M., O'Neill, A., Kowal, J., Loeffler, J. S., & Black, P. M. L. (1997). A phase I trial of a new recombinant human β-interferon (BG9015) for the treatment of patients with recurrent gliomas. Clinical Cancer Research, 3(3), 381-387.

A phase I trial of a new recombinant human β-interferon (BG9015) for the treatment of patients with recurrent gliomas. / Fine, Howard A.; Wen, Patrick Y.; Robertson, Michael; O'Neill, Anne; Kowal, Janis; Loeffler, Jay S.; Black, Peter M L.

In: Clinical Cancer Research, Vol. 3, No. 3, 1997, p. 381-387.

Research output: Contribution to journalArticle

Fine, HA, Wen, PY, Robertson, M, O'Neill, A, Kowal, J, Loeffler, JS & Black, PML 1997, 'A phase I trial of a new recombinant human β-interferon (BG9015) for the treatment of patients with recurrent gliomas', Clinical Cancer Research, vol. 3, no. 3, pp. 381-387.
Fine, Howard A. ; Wen, Patrick Y. ; Robertson, Michael ; O'Neill, Anne ; Kowal, Janis ; Loeffler, Jay S. ; Black, Peter M L. / A phase I trial of a new recombinant human β-interferon (BG9015) for the treatment of patients with recurrent gliomas. In: Clinical Cancer Research. 1997 ; Vol. 3, No. 3. pp. 381-387.
@article{ee51660e73da4e2e81306033ecd98026,
title = "A phase I trial of a new recombinant human β-interferon (BG9015) for the treatment of patients with recurrent gliomas",
abstract = "Primary brain tumors represent an important cause of cancer-related morbidity and mortality in the United States. Despite advances in neurosurgery and radiotherapy, the median survival of patients with malignant gliomas remains less than 1 year. A contributing factor to the poor prognoses of these patients is the diffuse, infiltrative nature of these tumors, which limits the effectiveness of focal therapies (i.e. surgery and radiation). Unfortunately, standard chemotherapy has been of limited benefit in the treatment of malignant gliomas, underlying the necessity for new drugs with novel mechanisms of action. On the basis of promising in vitro and clinical data demonstrating significant antiglioma activity of purified IFN-β and a synthetic IFN-β (Betaseron), we conducted a Phase I trial of a new, nonmutated, glycosylated recombinant human IFN-β (BG9015) in patients with recurrent, high-grade astrocytomas. In this trial, we demonstrate that the maximally tolerated dose of BG9015 is 6 million units/m2 delivered by intramuscular injection three times per week. Dose-limiting neurotoxicity was seen in both patients treated at 8 million units/m2. Additionally, we demonstrate that high BG9015 serum levels are associated with a fall in natural killer cell number, radiographic response, and prolonged survival. We conclude that BG9015 has activity in patients with malignant gliomas, although the therapeutic index may be narrow. Future studies will be needed to confirm the observation that natural killer cell number and activity as well as BG9015 serum levels are important markers of antitumor activity.",
author = "Fine, {Howard A.} and Wen, {Patrick Y.} and Michael Robertson and Anne O'Neill and Janis Kowal and Loeffler, {Jay S.} and Black, {Peter M L}",
year = "1997",
language = "English (US)",
volume = "3",
pages = "381--387",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - A phase I trial of a new recombinant human β-interferon (BG9015) for the treatment of patients with recurrent gliomas

AU - Fine, Howard A.

AU - Wen, Patrick Y.

AU - Robertson, Michael

AU - O'Neill, Anne

AU - Kowal, Janis

AU - Loeffler, Jay S.

AU - Black, Peter M L

PY - 1997

Y1 - 1997

N2 - Primary brain tumors represent an important cause of cancer-related morbidity and mortality in the United States. Despite advances in neurosurgery and radiotherapy, the median survival of patients with malignant gliomas remains less than 1 year. A contributing factor to the poor prognoses of these patients is the diffuse, infiltrative nature of these tumors, which limits the effectiveness of focal therapies (i.e. surgery and radiation). Unfortunately, standard chemotherapy has been of limited benefit in the treatment of malignant gliomas, underlying the necessity for new drugs with novel mechanisms of action. On the basis of promising in vitro and clinical data demonstrating significant antiglioma activity of purified IFN-β and a synthetic IFN-β (Betaseron), we conducted a Phase I trial of a new, nonmutated, glycosylated recombinant human IFN-β (BG9015) in patients with recurrent, high-grade astrocytomas. In this trial, we demonstrate that the maximally tolerated dose of BG9015 is 6 million units/m2 delivered by intramuscular injection three times per week. Dose-limiting neurotoxicity was seen in both patients treated at 8 million units/m2. Additionally, we demonstrate that high BG9015 serum levels are associated with a fall in natural killer cell number, radiographic response, and prolonged survival. We conclude that BG9015 has activity in patients with malignant gliomas, although the therapeutic index may be narrow. Future studies will be needed to confirm the observation that natural killer cell number and activity as well as BG9015 serum levels are important markers of antitumor activity.

AB - Primary brain tumors represent an important cause of cancer-related morbidity and mortality in the United States. Despite advances in neurosurgery and radiotherapy, the median survival of patients with malignant gliomas remains less than 1 year. A contributing factor to the poor prognoses of these patients is the diffuse, infiltrative nature of these tumors, which limits the effectiveness of focal therapies (i.e. surgery and radiation). Unfortunately, standard chemotherapy has been of limited benefit in the treatment of malignant gliomas, underlying the necessity for new drugs with novel mechanisms of action. On the basis of promising in vitro and clinical data demonstrating significant antiglioma activity of purified IFN-β and a synthetic IFN-β (Betaseron), we conducted a Phase I trial of a new, nonmutated, glycosylated recombinant human IFN-β (BG9015) in patients with recurrent, high-grade astrocytomas. In this trial, we demonstrate that the maximally tolerated dose of BG9015 is 6 million units/m2 delivered by intramuscular injection three times per week. Dose-limiting neurotoxicity was seen in both patients treated at 8 million units/m2. Additionally, we demonstrate that high BG9015 serum levels are associated with a fall in natural killer cell number, radiographic response, and prolonged survival. We conclude that BG9015 has activity in patients with malignant gliomas, although the therapeutic index may be narrow. Future studies will be needed to confirm the observation that natural killer cell number and activity as well as BG9015 serum levels are important markers of antitumor activity.

UR - http://www.scopus.com/inward/record.url?scp=0030935786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030935786&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 381

EP - 387

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 3

ER -